Literature DB >> 31514650

Using Cost-Effectiveness Evidence to Inform Decisions as to which Health Services to Provide.

John Cairns1.   

Abstract

Abstract-This article focuses on three challenges concerning the use of cost-effectiveness thresholds to inform decision making regarding which services a third-party payer will fund. First, how is the appropriate cost-effectiveness threshold or threshold range to be determined or, indeed, should there be a single threshold or multiple thresholds? Second, how can the valuation of health benefits be refined to better capture the value of treatments to patients and to the economy as a whole? Third, how is the tension between cost-effectiveness and the affordability and sustainability of health services to be managed?It concludes that whatever other factors are considered in addition to cost-effectiveness, and whether the decision-making process is more or less deliberative, cost-effectiveness thresholds are important. Though there is a range of sources for identifying appropriate thresholds, using the opportunity cost in terms of the health benefits from displaced activities will minimize the problem of cost-effective interventions not being affordable and will facilitate the efficient use of scarce resources. Finally, although experience using weighted quality-adjusted life years (QALYs) is currently very limited, it is likely to be an important area in the future.

Entities:  

Keywords:  QALYs ; cost-effectiveness threshold; decision making; drug adoption; health technology assessment

Year:  2016        PMID: 31514650     DOI: 10.1080/23288604.2015.1124172

Source DB:  PubMed          Journal:  Health Syst Reform        ISSN: 2328-8620


  3 in total

1.  Direct Medical Cost of Stroke and the Cost-Effectiveness of Direct Oral Anticoagulants in Atrial Fibrillation-Related Stroke: A Cross-Sectional Study.

Authors:  Siti Norain Azahar; Saperi Sulong; Wan Asyraf Wan Zaidi; Norliza Muhammad; Yusof Kamisah; Norliana Masbah
Journal:  Int J Environ Res Public Health       Date:  2022-01-19       Impact factor: 3.390

2.  Optimal health and economic impact of non-pharmaceutical intervention measures prior and post vaccination in England: a mathematical modelling study.

Authors:  Michael J Tildesley; Anna Vassall; Steven Riley; Mark Jit; Frank Sandmann; Edward M Hill; Robin N Thompson; Benjamin D Atkins; John Edmunds; Louise Dyson; Matt J Keeling
Journal:  R Soc Open Sci       Date:  2022-08-10       Impact factor: 3.653

3.  Protocol for a two-arm pragmatic stepped-wedge hybrid effectiveness-implementation trial evaluating Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship (ENCOMPASS).

Authors:  Marc Kowalkowski; Tara Eaton; Andrew McWilliams; Hazel Tapp; Aleta Rios; Stephanie Murphy; Ryan Burns; Bella Gutnik; Katherine O'Hare; Lewis McCurdy; Michael Dulin; Christopher Blanchette; Shih-Hsiung Chou; Scott Halpern; Derek C Angus; Stephanie P Taylor
Journal:  BMC Health Serv Res       Date:  2021-06-02       Impact factor: 2.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.